Moderna reported unaudited/preliminary product sales between $3 billion and $3.1 billion for 2024, toward the lower end of its previously issued guidance of $3.0-$3.5 billion. MRNA also reduced its previously announced sales guidance for 2025 by $1 billion and now expects total revenues in the range of $1.5 to $2.5 billion, down from the previously issued guidance of $2.5-$3.5 billion.